PL3483163T3 - Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2 - Google Patents

Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2

Info

Publication number
PL3483163T3
PL3483163T3 PL18206943T PL18206943T PL3483163T3 PL 3483163 T3 PL3483163 T3 PL 3483163T3 PL 18206943 T PL18206943 T PL 18206943T PL 18206943 T PL18206943 T PL 18206943T PL 3483163 T3 PL3483163 T3 PL 3483163T3
Authority
PL
Poland
Prior art keywords
triazolo
receptor antagonists
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
PL18206943T
Other languages
English (en)
Inventor
Stephan Roever
Mark Rogers-Evans
Matthias Nettekoven
Sébastien SCHMITT
Uwe Grether
Atsushi KIMBARA
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3483163T3 publication Critical patent/PL3483163T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18206943T 2013-09-06 2014-09-03 Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2 PL3483163T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13183385 2013-09-06
EP18206943.5A EP3483163B1 (en) 2013-09-06 2014-09-03 Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists
PCT/EP2014/068640 WO2015032769A1 (en) 2013-09-06 2014-09-03 Novel triazolo[4,5-d]pyrimidine derivatives
EP14761320.2A EP3041843B1 (en) 2013-09-06 2014-09-03 Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists

Publications (1)

Publication Number Publication Date
PL3483163T3 true PL3483163T3 (pl) 2021-11-22

Family

ID=49111076

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14761320T PL3041843T3 (pl) 2013-09-06 2014-09-03 Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2
PL18206943T PL3483163T3 (pl) 2013-09-06 2014-09-03 Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14761320T PL3041843T3 (pl) 2013-09-06 2014-09-03 Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2

Country Status (31)

Country Link
US (1) US9593123B2 (pl)
EP (3) EP3943497A1 (pl)
JP (1) JP6441356B2 (pl)
KR (3) KR20220140651A (pl)
CN (1) CN105555788B (pl)
AR (1) AR097553A1 (pl)
AU (1) AU2014317229B2 (pl)
CA (1) CA2915766C (pl)
CL (1) CL2016000495A1 (pl)
CR (1) CR20160076A (pl)
DK (2) DK3483163T3 (pl)
EA (1) EA028335B1 (pl)
ES (2) ES2714094T3 (pl)
HR (2) HRP20190361T1 (pl)
HU (2) HUE055201T2 (pl)
IL (1) IL243092B (pl)
LT (2) LT3483163T (pl)
MA (1) MA38826B1 (pl)
MX (2) MX391724B (pl)
MY (1) MY191628A (pl)
PE (2) PE20191528A1 (pl)
PH (1) PH12016500250B1 (pl)
PL (2) PL3041843T3 (pl)
PT (2) PT3041843T (pl)
RS (2) RS62234B1 (pl)
SG (1) SG11201601714UA (pl)
SI (2) SI3041843T1 (pl)
TR (1) TR201900662T4 (pl)
TW (1) TWI705966B (pl)
UA (1) UA116395C2 (pl)
WO (1) WO2015032769A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162630A1 (en) * 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN107074864B (zh) 2014-11-07 2019-12-27 豪夫迈·罗氏有限公司 作为大麻素受体2的激动剂的三唑并[4，5-d]嘧啶类
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017076266A1 (zh) * 2015-11-06 2017-05-11 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
EP3475280B1 (en) * 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
KR20230062680A (ko) * 2016-06-23 2023-05-09 에프. 호프만-라 로슈 아게 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP3475281A1 (en) 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
CN106478639B (zh) * 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432247B (zh) * 2016-09-27 2018-06-29 郑州大学 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用
CN106432248B (zh) * 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN106928296A (zh) * 2017-02-06 2017-07-07 上海华升生物科技有限公司 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法
CN107033148B (zh) * 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN106928235A (zh) * 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN109516990B (zh) * 2017-09-19 2021-06-01 天津药物研究院有限公司 嘧啶并三氮唑类化合物、其制备方法和用途
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用
CN119912457B (zh) * 2025-03-03 2025-10-10 郑州大学 嘧啶并三氮唑类化合物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011643A1 (en) 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CN101060841A (zh) * 2004-06-17 2007-10-24 加利福尼亚大学董事会 拮抗腺苷a2a受体来改善成瘾行为的一种或多种构成
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2013060837A1 (en) 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
EP3357918A1 (en) 2012-12-07 2018-08-08 F. Hoffmann-La Roche AG Novel pyridine derivatives
JP6426619B2 (ja) 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド
HRP20171459T1 (hr) 2012-12-07 2017-11-03 F. Hoffmann - La Roche Ag Piridin-2-amidi korisni kao agonisti cb2
PL2928882T3 (pl) 2012-12-07 2017-07-31 F.Hoffmann-La Roche Ag Pochodne pirazyny jako agoniści receptora cb2
UA118666C2 (uk) 2013-03-07 2019-02-25 Ф. Хоффманн-Ля Рош Аг Похідні піразолу
KR20160002857A (ko) 2013-05-02 2016-01-08 에프. 호프만-라 로슈 아게 CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체
HUE039589T2 (hu) 2013-05-02 2019-01-28 Hoffmann La Roche Purinszármazékok mint CB2 receptor agonisták
KR20160018543A (ko) 2013-06-11 2016-02-17 에프. 호프만-라 로슈 아게 신규한 테트라졸론 유도체

Also Published As

Publication number Publication date
EP3483163A3 (en) 2019-07-24
KR20210074404A (ko) 2021-06-21
EP3041843B1 (en) 2019-01-02
LT3041843T (lt) 2019-03-12
KR102349567B1 (ko) 2022-01-11
CA2915766C (en) 2023-09-26
MX2016002117A (es) 2016-07-05
PH12016500250B1 (en) 2019-09-13
PT3041843T (pt) 2019-02-26
PE20160691A1 (es) 2016-07-28
CN105555788A (zh) 2016-05-04
DK3483163T3 (da) 2021-08-30
EP3041843A1 (en) 2016-07-13
KR20220140651A (ko) 2022-10-18
HUE055201T2 (hu) 2021-11-29
AU2014317229A1 (en) 2016-01-07
EP3483163A2 (en) 2019-05-15
IL243092B (en) 2019-06-30
EA201690478A1 (ru) 2016-06-30
MY191628A (en) 2022-07-04
EA028335B1 (ru) 2017-11-30
PL3041843T3 (pl) 2019-06-28
MX2019009100A (es) 2019-09-16
AU2014317229B2 (en) 2018-11-08
JP2016532707A (ja) 2016-10-20
JP6441356B2 (ja) 2018-12-19
PH12016500250A1 (en) 2016-05-16
TW201542551A (zh) 2015-11-16
HRP20190361T1 (hr) 2019-04-05
MX391724B (es) 2025-03-21
US9593123B2 (en) 2017-03-14
SI3483163T1 (sl) 2021-11-30
TR201900662T4 (tr) 2019-02-21
RS58390B1 (sr) 2019-04-30
PE20191528A1 (es) 2019-10-23
UA116395C2 (uk) 2018-03-12
LT3483163T (lt) 2021-09-10
MX367084B (es) 2019-08-05
KR20160050061A (ko) 2016-05-10
HUE041760T2 (hu) 2019-05-28
HK1219277A1 (zh) 2017-03-31
SI3041843T1 (sl) 2019-04-30
ES2714094T3 (es) 2019-05-27
NZ756513A (en) 2021-05-28
DK3041843T3 (en) 2019-03-25
MA38826A1 (fr) 2016-05-31
CL2016000495A1 (es) 2016-10-07
WO2015032769A1 (en) 2015-03-12
EP3483163B1 (en) 2021-06-23
ES2883923T3 (es) 2021-12-09
IL243092A0 (en) 2016-02-01
PT3483163T (pt) 2021-08-24
HRP20211322T1 (hr) 2021-11-26
MA38826B1 (fr) 2016-12-30
CR20160076A (es) 2016-04-01
EP3943497A1 (en) 2022-01-26
US20160168158A1 (en) 2016-06-16
RS62234B1 (sr) 2021-09-30
TWI705966B (zh) 2020-10-01
NZ715085A (en) 2021-05-28
AR097553A1 (es) 2016-03-23
SG11201601714UA (en) 2016-04-28
KR102454344B1 (ko) 2022-10-14
CN105555788B (zh) 2018-11-23
CA2915766A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PT3483163T (pt) Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
ZA201402905B (en) [1,2,3]triazolo [4,5-d]pyrimidine derivatives as agonist of the cannabinoid receptor 2
IL240402A0 (en) Tetrahydroimidazo[d–5,1][4,1]oxazapine deriv
AP2014007899A0 (en) 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
IL232304A (en) [3,2,1] triazolo [5,4– d] pyrimidine derivatives as cannabinoid receptor type 2 agonists [3,2,1] triazolo [5,4– d] pyrimidine as cannabinoid receptor 2 agonists
IL242162B (en) Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
ZA201400875B (en) 5-flouro-4-imino-3-(substituted)-3,4-dihydropyrimidin-2-(1h)-one derivatives
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่